Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?

Yamanaka K, Chatterjee N, Hemann MT, Walker GC.

PLoS Genet. 2017 Aug 17;13(8):e1006842. doi: 10.1371/journal.pgen.1006842. eCollection 2017 Aug. No abstract available.

2.

PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes.

Soto-Feliciano YM, Bartlebaugh JME, Liu Y, Sánchez-Rivera FJ, Bhutkar A, Weintraub AS, Buenrostro JD, Cheng CS, Regev A, Jacks TE, Young RA, Hemann MT.

Genes Dev. 2017 May 15;31(10):973-989. doi: 10.1101/gad.295857.117. Epub 2017 Jun 12.

3.

Modeling Tumor Clonal Evolution for Drug Combinations Design.

Zhao B, Hemann MT, Lauffenburger DA.

Trends Cancer. 2016 Mar;2(3):144-158. doi: 10.1016/j.trecan.2016.02.001.

4.

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT.

Nat Med. 2017 Apr;23(4):461-471. doi: 10.1038/nm.4291. Epub 2017 Feb 27.

5.

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K.

Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13.

6.

Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations.

Sun D, Dalin S, Hemann MT, Lauffenburger DA, Zhao B.

Sci Rep. 2016 Nov 7;6:36198. doi: 10.1038/srep36198.

7.

Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage.

Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ.

Inorganica Chim Acta. 2016 Oct 1;452:125-129. Epub 2016 Mar 25.

8.

Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Barnes JC, Bruno PM, Nguyen HV, Liao L, Liu J, Hemann MT, Johnson JA.

J Am Chem Soc. 2016 Sep 28;138(38):12494-501. doi: 10.1021/jacs.6b06321. Epub 2016 Sep 14.

9.

A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses.

Bent EH, Gilbert LA, Hemann MT.

Genes Dev. 2016 Aug 15;30(16):1811-21. doi: 10.1101/gad.284851.116. Epub 2016 Aug 26.

10.

Targeting MTHFD2 in acute myeloid leukemia.

Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K.

J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20.

11.

Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.

Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3892-900. doi: 10.1073/pnas.1600582113. Epub 2016 Jun 20.

12.

Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia.

Wilson JL, Dalin S, Gosline S, Hemann M, Fraenkel E, Lauffenburger DA.

Integr Biol (Camb). 2016 Jul 11;8(7):761-74. doi: 10.1039/c6ib00040a. Epub 2016 Jun 17.

13.

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.

Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU.

Oncogene. 2016 Sep 29;35(39):5119-31. doi: 10.1038/onc.2016.41. Epub 2016 Mar 21.

14.

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT.

Cell. 2016 Mar 24;165(1):234-246. doi: 10.1016/j.cell.2016.01.045. Epub 2016 Feb 25.

15.

A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB.

Cancer Cell. 2015 Nov 9;28(5):623-637. doi: 10.1016/j.ccell.2015.09.009. Erratum in: Cancer Cell. 2015 Dec 14;28(6):831.

16.

The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies.

Shingleton JR, Hemann MT.

PLoS One. 2015 Nov 20;10(11):e0143275. doi: 10.1371/journal.pone.0143275. eCollection 2015.

17.

A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.

Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ.

J Am Chem Soc. 2015 Dec 2;137(47):14854-7. doi: 10.1021/jacs.5b10182. Epub 2015 Nov 18. Erratum in: J Am Chem Soc. 2016 Mar 9;138(9):3250.

18.

Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.

McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD.

Cancer Res. 2015 Aug 1;75(15):3127-38. doi: 10.1158/0008-5472.CAN-14-3616. Epub 2015 May 29.

19.

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, Hemann MT, Jiang H.

EMBO Mol Med. 2015 Apr;7(4):438-49. doi: 10.15252/emmm.201404580.

20.

A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth.

Meacham CE, Lawton LN, Soto-Feliciano YM, Pritchard JR, Joughin BA, Ehrenberger T, Fenouille N, Zuber J, Williams RT, Young RA, Hemann MT.

Genes Dev. 2015 Mar 1;29(5):483-8. doi: 10.1101/gad.254151.114.

Supplemental Content

Loading ...
Support Center